Amarin

Amarin

SCHEMBL17531553

CC(=O)OC(C)(C)/C=C/C(=O)[C@](C)(O)[C@H]1[C@H](O)C[C@@]2(C)C3CC=C4C(CC(O)C(=O)C4(C)C)[C@]3(C)C(=O)C[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGAL P20701 3/20 1.00
NPC1 O15118 2/20 1.00
RAB9A P51151 2/20 1.00
IGF2BP1 Q9NZI8 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
HIF1A Q16665 2/20 1.00
LMNA P02545 1/20 1.00
MAPT P10636 1/20 1.00
STAT3 P40763 1/20 1.00
HTT P42858 1/20 1.00
ATM Q13315 1/20 1.00
KMT2A Q03164 1/20 0.63
PAX8 Q06710 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ACHE P22303 2/20 0.58
CYP3A4 P08684 1/20 0.56
TYR P14679 1/20 0.39
PTPN1 P18031 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amarin SCHEMBL22433345 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL231815 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Cucurbitacin B SCHEMBL29602393 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL10013358 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL20121442 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL18177462 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL13668120 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL19186443 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL30863648 0.99 ITGAL (0.98) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Cucurbitacin E SCHEMBL29908892 0.92 ITGAL (0.84) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9718797-B2 Eight diasteromers of vittatalactone and methods of making, and methods of attracting acalymma vittatum The United States of America, as represented by the Secretary of Agirculture (US) 2017-08-01 US disclosed
US-9718797-B2 Eight diasteromers of vittatalactone and methods of making, and methods of attracting acalymma vittatum The United States of America, as represented by the Secretary of Agirculture (US) 2017-08-01 US disclosed
US-20160052901-A1 Eight Diasteromers of Vittatalactone and Methods of Making, and Methods of Attracting Acalymma vittatum CHEMVEDA LIFE SCIENCES, INC. 2016-02-25 US disclosed
US-20160052901-A1 Eight Diasteromers of Vittatalactone and Methods of Making, and Methods of Attracting Acalymma vittatum CHEMVEDA LIFE SCIENCES, INC. 2016-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052901-A1 Eight Diasteromers of Vittatalactone and Methods of Making, and Methods of Attracting Acalymma vittatum DAGLA, NOTUM, DAGLB ITGAL 1009/4885NPC1 893/4885RAB9A 3781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.